The Data Pulse Building a bilingual culture for data-first drug discovery with Daphne Koller (insitro)
12 snips
Jul 28, 2020 
Daphne Koller, Founder and CEO of Insitro, is a pioneer in merging machine learning with biomedicine. In the discussion, she emphasizes the importance of a bilingual culture that bridges biology and ML for innovative drug discovery. Koller shares insights on building hybrid teams, the challenges of large biomedical datasets, and how ML can enhance drug efficacy predictions. She also highlights successful strategies for managing clinical trials and encourages integrating data scientists into early decision-making in pharma. A must-listen for anyone interested in the future of healthcare!
AI Snips
Chapters
Transcript
Episode notes
Why Biology Attracted ML Researchers
- Biology became compelling because its data and problems were far richer than traditional ML benchmarks.
- Daphne Koller stayed in the field because ML could impact human health at scale.
Scale Enables New ML In Biomedicine
- Big data in biomedicine is finally real with cohorts of tens or hundreds of thousands and millions of single cells.
- These scales enable new ML methods but require domain-specific algorithm development.
Prioritize Culture When Building Teams
- Build culture deliberately to make teams act autonomously and move quickly in the right direction.
- Hire people who can live and improve that culture rather than just fill roles.